<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124106</url>
  </required_header>
  <id_info>
    <org_study_id>Clinical Protocol (MIB)</org_study_id>
    <nct_id>NCT05124106</nct_id>
  </id_info>
  <brief_title>In Vivo Proof-of-principle Study of Raman Spectroscopy in Trial Participants With Bladder Tumours</brief_title>
  <official_title>In Vivo Proof-of-principle Study of Raman Spectroscopy in Trial Participants With Bladder Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proff Dr JÃ¼rgen Popp, Leibniz Institute, IPHT, Jena, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karin Mogensen urologist, Herlev hospital, Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Proff Dr Iwan Schie, Leibniz Institute, IPHT, Jena, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose with this clinical investigation is to perform Raman spectroscopy inside the&#xD;
      vivid bladder and to acquire Raman spectra of normal and tumour bladder tissue, and in a&#xD;
      post-processing step to determine the grade of the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose with this clinical investigation is to perform Raman spectroscopy inside the&#xD;
      vivid bladder and to acquire Raman spectra of normal and tumour bladder tissue, and in a&#xD;
      post-processing step to determine the grade of the bladder tumor.&#xD;
&#xD;
      The recordings and overall results will be compared to standard histo/cytopathological&#xD;
      examination of urological tissue to achieve a clinical useful concordance between gold&#xD;
      standard histo/cytopathological diagnosis and diagnostic information established by Raman.&#xD;
&#xD;
      The MIB RAMAN SYSTEM in combination with a Raman probe will be used in the operating theatre&#xD;
      at Herlev/Copenhagen hospital urology department, where the rigid resectoscopes will be used&#xD;
      while the trial participant is under general anesthesia. Each measurement takes about 1-5&#xD;
      seconds and the whole procedure with the fiber optic probes is expected to prolong the&#xD;
      operation with 10-15 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Tumor identified during endoscopy of the bladder is examined with Raman spectrometry. Tumor is resected. Histopathological diagnosis is compared with results of Raman spectrometry.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patient tumor stage is unknown for the examiner.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of tumor grade by Raman spectometry</measure>
    <time_frame>4 weeks</time_frame>
    <description>To achieve a clinical useful concordance between gold standard histo/cytopathological diagnosis and the information provided through Raman spectroscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate feasibility of handling the diagnostic optic equipment (MIB RAMAN SYSTEM), the Raman probe and the software, when the urologist examines the bladder for lesions.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Examine results on the sensitivity and specificity for &quot;diagnosis&quot; (normal tissue/tumour) in 30 trial participants using the developed MIB RAMAN SYSTEM.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endoscopic Bladder Cancer Diagnosis With Raman</condition>
  <arm_group>
    <arm_group_label>Diagnostic ability of Raman spectrometry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Raman spectrometry during endoscopic bladder cancer surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Raman Spectrometry</intervention_name>
    <description>Bladder tumor is examined with Raman spectrometry during endoscopy</description>
    <arm_group_label>Diagnostic ability of Raman spectrometry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        After booking for surgery the trial participants will be informed orally about the study&#xD;
        and written material will be given by a doctor or nurse form the study group. If the trial&#xD;
        participant accept to enter the study, written informed consent will be obtained. The trial&#xD;
        participant will be informed that they can withdraw the informed consent at any time and&#xD;
        the treatment will be according to the guidelines of the department.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macroscopic hematuria&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Expected poor compliance&#xD;
&#xD;
          -  Persons &lt; 18 years&#xD;
&#xD;
          -  Persons who do not read or understand Danish&#xD;
&#xD;
          -  Dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gregers G Hermann, DM Sc</last_name>
    <phone>+45 38686801</phone>
    <email>gregers.gautier.hermann@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Mogensen, MD</last_name>
    <phone>+45 38686802</phone>
    <email>Karin.Mogensen@regionh.dk</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Gregers Gautier Hermann</investigator_full_name>
    <investigator_title>Consultant Urologist</investigator_title>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Raman spectrometry</keyword>
  <keyword>In vivo diagnostics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

